MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer

Acquired resistance is inevitable in non–small cell lung cancers (NSCLCs) treated with osimertinib (OSI), and the mechanisms are not well defined. The MERTK ligand GAS6 promoted downstream oncogenic signaling in EGFR-mutated (EGFRMT) NSCLC cells treated with OSI, suggesting a role for MERTK activati...

Full description

Bibliographic Details
Main Authors: Dan Yan, Justus M. Huelse, Dmitri Kireev, Zikang Tan, Luxiao Chen, Subir Goyal, Xiaodong Wang, Stephen V. Frye, Madhusmita Behera, Frank Schneider, Suresh S. Ramalingam, Taofeek Owonikoko, H. Shelton Earp, Deborah DeRyckere, Douglas K. Graham
Format: Article
Language:English
Published: American Society for Clinical Investigation 2022-08-01
Series:The Journal of Clinical Investigation
Subjects:
Cell biology
Oncology
Online Access:https://doi.org/10.1172/JCI150517

Internet

https://doi.org/10.1172/JCI150517

Similar Items